Payers Review Process and Effective Strategies for PDT Coverage

Paul Jeffrey, PharmD, presents the findings of a study, which investigated patient engagement and clinical outcomes associated with the use of prescription digital therapeutics (PDTs) in the treatment of substance use disorders, and discusses the need for further research to advance the efficacy and value of PDTs in this field.

EP: 1.Differentiating PDTs from Wellness Apps and Evaluating Efficacy

EP: 2.Payer Needs and Strategies for Evaluating and Covering PDTs

Now Viewing

EP: 3.Payers Review Process and Effective Strategies for PDT Coverage

EP: 4.Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

EP: 5.Dawn of the Age of Adopting PDTs

EP: 6.Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

EP: 7.Evolving Commercialization and Distribution Models for PDTs

EP: 8.Promoting Appropriate PDT Prescribing Through Provider Education and Support

EP: 9.Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

EP: 10.Optimizing Benefit Design and Implementation for Improved PDT Access

EP: 11.PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Related Videos

Related Content

Advertisement

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 3rd 2025

Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

Brooke McCormick

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, intestinal problems, and a higher 30-day readmission rate.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 3rd 2025

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

Julia Bonavitacola

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

April 1st 2025

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

Maggie L. Shaw

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.

Related Content

Advertisement

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

April 3rd 2025

Obesity May Increase Surgical Complications in Epithelial Ovarian Cancer

Brooke McCormick

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, intestinal problems, and a higher 30-day readmission rate.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

April 3rd 2025

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

Julia Bonavitacola

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish efficacy, according to the FDA.

April 1st 2025

MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe

Maggie L. Shaw

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.